scholarly journals Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases

2015 ◽  
Vol 16 (9) ◽  
pp. 20841-20858 ◽  
Author(s):  
Eddy Owaga ◽  
Rong-Hong Hsieh ◽  
Beatrice Mugendi ◽  
Sakhile Masuku ◽  
Chun-Kuang Shih ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Th17 Cells ◽  
Therapeutic Targets ◽  
Bowel Diseases ◽  
Inflammatory Bowel

NEUTROPHIL EXTRACELLULAR TRAPS IN INFLAMMATORY BOWEL DISEASES: IMPLICATIONS IN PATHOGENESIS AND THERAPEUTIC TARGETS

2021 ◽  
pp. 105779
Author(s):  
Anderson dos Santos Ramos ◽  
Giovana Cristina Santana Viana ◽  
Marcelo de Macedo Brigido ◽  
Juliana Franco Almeida
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Therapeutic Targets ◽  
Neutrophil Extracellular Traps ◽  
Extracellular Traps ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Pascale Quatresooz ◽  
Trinh Hermanns-Lê ◽  
Gérald E. Piérard ◽  
Philippe Humbert ◽  
Philippe Delvenne ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Inflammatory Bowel Diseases ◽  
T Helper Cells ◽  
Th17 Cells ◽  
Human Monoclonal Antibody ◽  
Biologic Therapies ◽  
T Helper ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Th 1

Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.

Sign in / Sign up

Export Citation Format

Share Document